Skip to content
legitretatrutide
legitretatrutide

CHECK RETATRUTIDE SOURCES

Where can you check the retatrutide papers?

Each claim names its paper. PubMed is a medical paper library, while a DOI gives one paper a permanent link.

Where does each retatrutide number come from?

A large weight change may make you want to see the paper yourself. The claims here lead to 13 published sources. PubMed is a medical paper library. A DOI gives one paper a permanent address on the web. The retatrutide references use the same source numbers, from [1]–[13], on each page.

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. ↗
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. ↗
  3. Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. ↗
  4. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. ↗
  5. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. ↗
  6. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. ↗
  7. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers. Metabol Open. 2024. ↗
  8. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist: a systematic review and meta-analysis. Proc (Bayl Univ Med Cent). 2025. ↗
  9. Retatrutide showing promise in obesity (and type 2 diabetes). Expert Opin Investig Drugs. 2023. ↗
  10. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis. Diabetes Obes Metab. 2025. ↗
  11. Coskun T, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a randomised, double-blind, placebo- and active-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2025. ↗
  12. Neumann J, et al. Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart. Pharmaceutics. 2026;18(4):447. ↗
  13. Cooper ME, et al. GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. J Clin Invest. 2025;135(21):e194749. ↗